VeruVERU
About: Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
Employees: 233
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
127% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 15
87% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 15
61% more call options, than puts
Call options by funds: $697K | Put options by funds: $434K
42% more capital invested
Capital invested by funds: $35.9M [Q1] → $51M (+$15M) [Q2]
14% more funds holding
Funds holding: 92 [Q1] → 105 (+13) [Q2]
6.32% more ownership
Funds ownership: 35.05% [Q1] → 41.37% (+6.32%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for VERU.